ACTION INTERFERONS AND IFN-INDUCTORS ON TLR/RLRS GENES EXPRESSION AND DIFFERENTIATION OF TUMOR CELL LINES THP-1 AND HCT-116


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study of known interferons (IFN) type I and IFN-inductors drugs different chemical structure on cell differentiation and expression group of genes of TLR/RLRs, referring to group of pattern-recognition receptors. Materials and methods. Cellular lines ТНР-1 (acute monocytic leukemia) и НСТ-116 (colon adenocarcinoma) were treated by interferons drugs Reaferon, Altevir, Genfakson, Infibeta 105-106 МЕ, IFN-inductors Ridostin 102-103 ßg/ml, Cycloferon 625 ßg/ml and Imunomax 2 МЕ during 24 h or 96 h at 37 °С. Gene expression were estimated by method qRT-PCR (CFX-96, Bio-Rad). CD-immuno-phenotypes of ТНР-1 cells were detected by flow cytometric fluorescence method with FITC and PE monoclonal antibodies (FACSCanto II, Becton Dickinson). Results. It was shown that tumor cells THP-1 and HCT-116 have low and variable constitutive levels gene expression of TLR-receptors 2, 3, 4, 7, 8, 9 during passages. This gene status may be connected with incorrect processing of mature mRNA forms. Genes TLR4, TLR8 and factor NFkB are stimulated by interferons and IFN-inductors more high in THP-cells and genes TLR7, TLR8, TLR9 and NFkB - in HCT-cells. Ridostin (mix ssRNA and dsRNA S. cerevisiae) is the best activator of TLR/RLRs receptors. Ridostin increases macrophage marker CD11b, Cycloferon, Imunomax stimulate levels of early T-cell antigen CD7, interferons results in growth of HLA DR. The drugs Cycloferon, Imunomax and Reaferon decrease levels of myeloid suppressor CD38. Conclusion. Group of recombinant IFNs and IFN-inductor drugs various chemical structures regulate TLR/RLRs genes expression differently in THP-1 and HCT-116. TLR/RLRs genes activation are accompanied by CD-phenotypes changes in THP-1 monocytic cell line.

About the authors

T. M. Sokolova

ФГБУ«ФНИЦэпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава России

Author for correspondence.
Email: tmsokolovavir@mail.ru
Russian Federation

V. V. Poloskov

ФГБУ«ФНИЦэпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава России

Russian Federation

O. S. Burova

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

A. N. Shuvalov

ФГБУ«ФНИЦэпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава России

Russian Federation

Z. A. Sokolova

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

A. N. Inshakov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

Yu. V. Shishkin

ФГБУ«ФНИЦэпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава России

Russian Federation

F. I. Ershov

ФГБУ«ФНИЦэпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава России

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.